Medicine and Dentistry
Transthyretin
100%
Amyloidosis
93%
ATTR Amyloidosis
46%
Disease
40%
Bone Scintigraphy
33%
Systematic Review
31%
Advanced Glycation End-Product
26%
AL Amyloidosis
23%
Radioactive Tracer
22%
Cardiomyopathy
22%
Heart Failure with Preserved Ejection Fraction
21%
Amyloid Cardiomyopathy
21%
Intima-Media Thickness
21%
Artery
20%
Systemic Lupus Erythematosus
20%
Autofluorescence
20%
Positron Emission Tomography
20%
Immunoglobulin Light Chain
20%
Myocardial Disease
20%
Polyneuropathy
18%
Biological Marker
17%
Scintigraphy
15%
6 N Carboxymethyllysine
14%
Heart Failure
13%
Heart Amyloidosis
13%
Prevalence
13%
Technetium-99
12%
Receptor
12%
Amyloid
12%
Light Chain
12%
Autologous Stem Cell Transplantation
12%
Disease Severity
11%
AA Amyloidosis
11%
Nuclear Medicine
11%
Atrial Fibrillation
10%
Quality of Life
10%
Brain Natriuretic Peptide
10%
Amino Terminal Sequence
10%
Neurofilament
10%
Florbetaben (18F)
10%
Molecular Imaging
10%
Oxidative Stress
10%
Aspiration
10%
Rheumatoid Arthritis
10%
Tosylchloramide Sodium
10%
Granulomatosis with Polyangiitis
10%
Overall Survival
10%
(3 Iodobenzyl)guanidine
10%
Cohort Analysis
10%
Heart Innervation
10%
Keyphrases
ATTR Amyloidosis
37%
AL Amyloidosis
36%
Bone Scintigraphy
32%
Cardiomyopathy
26%
Light Chain Amyloidosis
24%
Immunoglobulin Light Chains
24%
Cardiac Involvement
21%
Transthyretin
21%
Small Artery Elasticity
20%
Transthyretin Amyloidosis
20%
Wild-type Transthyretin Amyloidosis
20%
Overall Survival
17%
Hematological Response
17%
Amyloidosis
16%
Serum Amyloid A
14%
Dutch
13%
ATTRv
12%
Technetium-99m
11%
ATTRwt
10%
Heart Failure with Preserved Ejection Fraction (HFpEF)
10%
Rheumatoid Arthritis
10%
Real-life Cohort
10%
Intimal Thickening
10%
Patient Cohort
10%
Chloramine
10%
123Iodine
10%
Median Overall Survival
10%
SRAGE
10%
Advanced Disease
10%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
10%
Pathophysiological Pathways
10%
Life Functioning
10%
Positron Emission Tomography
10%
Protein Amyloids
10%
C-reactive Protein
10%
Physical Function
10%
Polyneuropathy
10%
Autoinflammatory Diseases
10%
Nuclear Imaging
10%
Nuclear Molecular Imaging
10%
Atrial Fibrillation
10%
Florbetaben
10%
Early Follow-up
10%
High-sensitivity Cardiac Troponin
10%
Patients with Heart Failure
10%
Transthyretin Amyloid Cardiomyopathy
10%
Quality of Life
10%
Regret
10%
Vutrisiran
10%
Systemic Amyloidosis
10%
Pharmacology, Toxicology and Pharmaceutical Science
Amyloidosis
64%
Transthyretin
60%
Disease
49%
ATTR Amyloidosis
46%
Advanced Glycation End Product
26%
Polyneuropathy
25%
Biological Marker
25%
Amyloid
23%
Systemic Lupus Erythematosus
20%
Wegener Granulomatosis
20%
Tracer
18%
6 N Carboxymethyllysine
14%
Inflammation
13%
Receptor
13%
AL Amyloidosis
12%
Technetium 99m
12%
Cohort Study
12%
AA Amyloidosis
11%
Disease Severity
11%
Carotid Atherosclerosis
10%
Placebo
10%
Heart Failure with Preserved Ejection Fraction
10%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
10%
Florbetaben
10%
Glucocorticoid
10%
Immunoglobulin Light Chain
10%
Prevalence
10%
Overall Survival
10%
Cardiomyopathy
10%
Myocardial Disease
10%
Neuropathy
8%
Disease Exacerbation
6%
Lysine
6%
Alkadiene
6%
Multiple Organ Failure
6%
Vascular Cell Adhesion Molecule 1
5%
Patisiran
5%
Atherosclerosis
5%
Essential Hypertension
5%
Diabetic Neuropathy
5%
Melphalan
5%
